DUBLIN--(BUSINESS WIRE)--The "Antidepressants Global Market Report 2020-30: COVID 19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.
The global antidepressants market is expected to grow from $14.3 billion in 2019 to about $28.6 billion in 2020 as mental health issues are expected to surge due to the effects of the COVID-19 pandemic making an impact on the global economy. The market is expected to stabilize and reach $19 billion at a CAGR of 7.4% through 2023.
The antidepressants market has also surged during the COVID-19 outbreak. The increasing number of cases and fatalities is affecting mental health by elevating anxiety worldwide. People who are already living with mental health problems are experiencing increased stress levels over the COVID-19 outbreak. This has triggered the demand for antidepressant drugs.
This report from the publisher covers this critical market and the impact on it from the COVID-19 virus. It provides strategists, marketers and senior management with the critical information they need to assess the increasing demand for antidepressants which play a critical role in the treatment of patients with COVID-19.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies
- Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates
- Create regional and country strategies on the basis of local data and analysis
- Identify growth segments for investment
- Outperform competitors using forecast data and the drivers and trends shaping the market
- Understand customers based on the latest market research findings
- Benchmark performance against key competitors
- Utilize the relationships between key data sets for superior strategizing
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3 working days of order
The antidepressants market covered in this report is segmented by product into selective serotonin reuptake inhibitor (SSRI); serotonin-norepinephrine reuptake inhibitor (SNRI); tricyclic antidepressant (TCA); monoamine oxidase inhibitor (MAOI); other products. It is also segmented by drug class into monoamine oxidase inhibitors; serotonin antagonist and reuptake inhibitors; serotonin-norepinephrine reuptake inhibitors; selective serotonin reuptake inhibitors; tricyclic antidepressants; others and by depressive disorder into major depressive disorder; obsessive-compulsive disorder; generalized anxiety disorder; panic disorder; others.
In May 2018, Allergan, an Ireland based company, focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world acquired Aptinyx for an unclosed amount. Through this acquisition Allergan gained important insights into NMDA receptor modulation as a potential therapeutic approach for depression. Aptinyx, a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders.
The side-effects and patent expiry of antidepressant drugs is a key factor hampering the growth of the antidepressant market. The antidepressants are Lexapro (escitalopram) and Celexa (citalopram), both of which are used to treat depression. Lexapro also helps for anxiety. Lexapro and Celexa can cause side effects common to others which includes nausea, sleeplessness, sweating, dry mouth and drowsiness. Celexa and Lexapro are both at risk for even more serious side effects including excessive bleeding, seizures and vision issues. In 2018 the labels of the medications contained a black box warning for an increased suicide risk. Therefore, the side-effects and patent expiry of antidepressant drugs is expected to limit the growth of the antidepressant market.
Key Topics Covered:
1. Executive Summary
2. Antidepressants Market Characteristics
3. Antidepressants Market Size And Growth
3.1. Global Antidepressants Historic Market, 2015 - 2019, $ Billion
3.2. Global Antidepressants Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
4. Antidepressants Market Segmentation
4.1. Global Antidepressants Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.2. Global Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.3. Global Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $
5. Antidepressants Market Regional And Country Analysis
5.1. Global Antidepressants Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Antidepressants Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
Companies Mentioned
- Smiths Medical Inc.
- Koninklijke Philips N.V.
- Vyaire Medical
- Schiller AG
- General Electric Company
- Masimo Corporation
- Medtronic PLC
- Opto Circuits Limited
- Fukuda Sangyo Co. Ltd
- Hill-Rom Holdings, Inc.
- MGC Diagnostics Corporation
- Messe Dsseldorf GmbH
- Omron Healthcare Inc.
- Nonin Medical, Inc
- Edwards Lifesciences Corporation
- Drgerwerk AG & Co. KGaA
- Spacelabs Healthcare Inc.
- Halma PLC
- SDI Diagnostics Inc
- nSpire Health, Inc
- SIBELMED
- Labtech Ltd.
- Carefusion Corporation
- NDD Medical Technologies, Inc.
- Vitalograph
- COSMED srl
- Philips Benelux
- Contec Medical System Co. Ltd
-
B Smiths Group plc.
For more information about this report visit https://www.researchandmarkets.com/r/l37105
